Predictors and outcomes of patients with COVID-19 admitted to intensive care units in Pakistan and the development of nosocomial fungal infections: Findings and implications.

COVID-19 Fungal infections Hospitalization Intensive care units Mortality Pakistan

Journal

IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676

Informations de publication

Date de publication:
Dec 2024
Historique:
received: 06 08 2024
revised: 03 09 2024
accepted: 03 09 2024
medline: 22 10 2024
pubmed: 22 10 2024
entrez: 22 10 2024
Statut: epublish

Résumé

Patients with COVID-19 admitted to intensive care units (ICUs) typically have many complications and co-morbidities, including secondary bacterial and fungal infections, which increase morbidity and mortality. The first step to address this is to measure the prevalence rates, predictors of fungal infections, and outcomes of patients with COVID-19 admitted to ICUs in Pakistan. Retrospective review of medical records of patients admitted with COVID-19 to the ICUs of six tertiary care hospitals in Pakistan between March 2020 and June 2023. A total of 636 patients were included; 68.9% were aged ≥50 years and 62.6% were male. Diabetes mellitus was the commonest co-morbidity (23.7%). A total of 67.8% of patients had severe COVID-19, with 23% critical cases. Antibiotics and antipyretics (all patients) were the most frequently prescribed medicines, along with corticosteroids (72.5%). A total of 63 nosocomial fungal infections developed in 53 patients, with mechanical ventilation and tracheal intubation being significant predictors of secondary fungal infections among patients with COVID-19. The mortality rate was 4.9%, with secondary fungal infections significantly associated with higher mortality. Approximately 8% of patients with COVID-19 admitted to the ICUs of tertiary developed secondary fungal infections associated with greater mortality. The key factors associated with secondary fungal infections need to be carefully monitored to reduce future mortality in these patients. We will continue to monitor the situation.

Identifiants

pubmed: 39435376
doi: 10.1016/j.ijregi.2024.100445
pii: S2772-7076(24)00116-4
pmc: PMC11492131
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100445

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors have no competing interests to declare.

Auteurs

Zia Ul Mustafa (ZU)

Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia.
Department of Pharmacy Services, District Headquarter (DHQ) Hospital, Pakpattan, Pakistan.

Aneeqa Suleman (A)

Department of Medicine, Tehsil Head Quarter Hospital, Darya Khan, District Bhakkar, Pakistan.

Muhammad Faiq Masood (MF)

Department of Medicine, Ameer-Ud-Din Medical College, Lahore, Pakistan.

Muhammad Salman (M)

Institute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore, Pakistan.

Aftab Nazir (A)

Department of Community Medicine, Niazi Medical and Dental College, Sargodha, Pakistan.

Tauqeer Hussain Mallhi (TH)

Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.

Yusra Habib Khan (YH)

Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.

Steward Mudenda (S)

Department of Pharmacy, School of Health Sciences, University of Zambia, Lusaka, Zambia.

Johanna C Meyer (JC)

Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, Pretoria, South Africa.

Brian Godman (B)

Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
Strathclyde Institute of Pharmacy and Biomedical Science (SIPBS), University of Strathclyde, Glasgow, UK.

R Andrew Seaton (RA)

Queen Elizabeth University Hospital, Glasgow, UK.
Scottish Antimicrobial Prescribing Group, Healthcare Improvement Scotland, Glasgow, UK.

Classifications MeSH